KURATA YASUSHI
No ORCID on file
· 21 papers in corpus
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…
1998
Compounds represented by general formula (I) or pharmaceutically acceptable salts thereof and a process for producing the same. Because of having an inhibitory activity on the bonding of progesterone to its receptor, these compounds are usa…